Overview

Alvogen has built a solid growth platform across the CEE region. Central & Eastern Europe therefore represents a strong platform for growth, with excellent manufacturing facilities in Romania and a packaging centre in Serbia serving the entire region. 

The group has enjoyed successful product launches in all markets and has the potential to catalyze growth even further in countries such as Russia, the Commonwealth of Independent States (CIS) and the Balkan region.

CEE commercial network
17
Biosimilars on the market
3

Portfolio

Biosimilar platform

Robust portfolio of biosimilars consists of leading molecules for the treatment of oncology, rheumatoid arthritis and anemia. Generic and OTC portfolio is sold via retain and hospital channels. Connect with our local teams for further information on product offering. 

Alvogen CEE

Broad commercial network

The CEE region is one of Alvogen’s most diverse regional hubs, it covers sales in: Croatia, Bulgaria, Romania, the Baltics, Poland, Hungary, Lithuania, Estonia, Latvia, Albania, Bosnia Herzegovina, Kosovo, Macedonia, Montenegro, Serbia, Russia, Kazakhstan, Ukraine, Moldova, Belarus and Azerbaijan.

Regional network

“We already have a strong geographical reach in the region and a solid pipeline of generics, biosimilars and OTC’s. Thanks to high rate of generic penetration, Central & Eastern Europe remains one of the most attractive regions for generics”
- Hacho Hatchikian, EVP of Sales in CEE region